NCT02040376View on ClinicalTrials.gov

Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 13, 2014

Primary Completion Date

December 15, 2017

Study Completion Date

December 15, 2017

Conditions
Brain Tumor Treated With Cranial or Cranial-Spinal Radiation
Interventions
DRUG

Metformin

Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

DRUG

Placebo

Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

Trial Locations (1)

M5G 1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT02040376 - Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma | Biotech Hunter | Biotech Hunter